Drs. Christopher Gibbons and Roy Freeman–two of the founders of CND Life Sciences who also serve as senior medical advisors–recently had their research on orthostatic hypotension as an early sign of Parkinson’s disease and dementia highlighted in a New York Times article.
CND In the News
CND Founders’ Research in the New York Times

CND Life Sciences
CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.